Literature DB >> 23174917

End-organ protection in cardiac surgery.

F De Somer1.   

Abstract

Mortality and morbidity postcardiac surgery with cardiopulmonary bypass (CPB) remain relative stable over the last decades, while the number of patients with increased comorbidity and more complex cardiac disease increases. Nevertheless, end-organ dysfunction and/or failure remain an issue. Multiple perioperative variables, such as non-optimal oxygen delivery, manipulation of the aorta, hyperlactatemia, type of anesthesia, surgical procedure and myocardial protection can be hold responsible for end-organ failure postcardiac surgery. However, it becomes more and more evident that also pre-existing factors, such as metabolic syndrome, renal insufficiency, hypertension, stroke and infection exacerbate mortality and morbidity. Unfortunately, these predisposing risk factors cannot be influenced perioperatively. Therefore, therapy should focus on controlling perioperative variables that, in combination with the predisposing factors, will further exacerbate organ dysfunction. In order to achieve this, more emphasis should be given to a patient-specific, goal-directed perfusion approach. This review will mainly focus on the impact of perioperative variables.

Entities:  

Mesh:

Year:  2012        PMID: 23174917

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  8 in total

1.  Lean Flow: Optimizing Cardiopulmonary Bypass Equipment and Flow for Obese Patients-A Technique Article.

Authors:  Joshua M Blessing; Jeffrey B Riley
Journal:  J Extra Corpor Technol       Date:  2017-03

2.  High veno-arterial carbon dioxide gradient is not predictive of worst outcome after an elective cardiac surgery: a retrospective cohort study.

Authors:  Jerome Morel; Nathalie Grand; Gregory Axiotis; Jean Baptiste Bouchet; Michael Faure; Christian Auboyer; Marco Vola; Serge Molliex
Journal:  J Clin Monit Comput       Date:  2016-03-04       Impact factor: 2.502

Review 3.  Protective lung ventilation during general anesthesia: is there any evidence?

Authors:  Silvia Coppola; Sara Froio; Davide Chiumello
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

4.  Hydrogen-rich solution attenuates myocardial injury caused by cardiopulmonary bypass in rats via the Janus-activated kinase 2/signal transducer and activator of transcription 3 signaling pathway.

Authors:  Keyan Chen; Yingjie Sun; Yugang Diao; Tiezheng Zhang; Wanwei Dong
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

5.  Tissue oxygen saturation changes and postoperative complications in cardiac surgery: a prospective observational study.

Authors:  Sabino Scolletta; Federico Franchi; Elisa Damiani; Armando Cennamo; Roberta Domizi; Antonio Meola; Claudia Scorcella; Davide Vanoli; Christopher Münch; Erica Adrario; Luca Marchetti; Fabio Silvio Taccone; Abele Donati
Journal:  BMC Anesthesiol       Date:  2019-12-16       Impact factor: 2.217

6.  Preoperative endothelial dysfunction in cutaneous microcirculation is associated with postoperative organ injury after cardiac surgery using extracorporeal circulation: a prospective cohort study.

Authors:  Stanislas Abrard; Olivier Fouquet; Jérémie Riou; Emmanuel Rineau; Pierre Abraham; Cyril Sargentini; Yannick Bigou; Christophe Baufreton; Sigismond Lasocki; Samir Henni
Journal:  Ann Intensive Care       Date:  2021-01-07       Impact factor: 6.925

Review 7.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

8.  Blood cytokine expression correlates with early multi-organ damage in a mouse model of moderate hypothermia with circulatory arrest using cardiopulmonary bypass.

Authors:  Ruslan Natanov; Faikah Gueler; Christine S Falk; Christian Kühn; Ulrich Maus; Erin C Boyle; Thierry Siemeni; Ann-Katrin Knoefel; Serghei Cebotari; Axel Haverich; Nodir Madrahimov
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.